SCHEMBL4593641

SCHEMBL4593641

COc1cc2c(Nc3ncc(CCNC(=O)c4cccc(F)c4)s3)ncnc2cc1OCCCN1CCCC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 16/20 0.75
EGFR P00533 5/20 0.62
KDR P35968 5/20 0.62
AURKB Q96GD4 4/20 0.62
SRC P12931 2/20 0.62
IGF1R P08069 1/20 0.62
FGFR1 P11362 1/20 0.62
FGFR2 P21802 1/20 0.62
FGFR4 P22455 1/20 0.62
FGFR3 P22607 1/20 0.62
CDK2 P24941 1/20 0.62
CSK P41240 1/20 0.62
JAK3 P52333 1/20 0.62
PTK2 Q05397 1/20 0.62
ROCK2 O75116 1/20 0.53
ALDH1A1 P00352 1/20 0.53
LCK P06239 1/20 0.53
FYN P06241 1/20 0.53
RET P07949 1/20 0.53
MET P08581 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4594619 0.93 AURKA (0.64) AURKAEGFRKDRAURKBSRC
SCHEMBL5174881 0.85 AURKB (0.75) AURKAEGFRKDRAURKBSRC
SCHEMBL4594617 0.82 AURKA (0.70) AURKAEGFRKDRAURKBSRC
SCHEMBL5140989 0.79 AURKB (0.85) AURKAEGFRKDRAURKBSRC
SCHEMBL5045676 0.78 AURKB (0.88) AURKAEGFRKDRAURKBSRC
SCHEMBL3885729 0.78 AURKB (0.79) AURKAEGFRKDRAURKBSRC
SCHEMBL5041520 0.77 AURKB (0.80) AURKAEGFRKDRAURKBSRC
SCHEMBL5045154 0.77 AURKB (1.00) AURKAEGFRKDRAURKBSRC
SCHEMBL31060166 0.77 AURKB (1.00) AURKAEGFRKDRAURKBSRC
SCHEMBL5041115 0.77 AURKB (0.83) AURKAEGFRKDRAURKBSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1948651-A1 THIAZOLE ANALOGUES AND USES THEREOF 4SC AG (DE) 2008-07-30 EP disclosed
US-20070149523-A1 Thiazole Analogues and Uses Thereof 4SC AG (DE) 2007-06-28 US disclosed
US-20070149523-A1 Thiazole Analogues and Uses Thereof 4SC AG (DE) 2007-06-28 US disclosed
US-20070149523-A1 Thiazole Analogues and Uses Thereof 4SC AG (DE) 2007-06-28 US disclosed
WO-2007054357-A1 THIAZOLE ANALOGUES AND USES THEREOF 4SC AG (DE) 2007-05-18 WO disclosed
EP-1785420-A1 Thiazole analogues and uses thereof 4SC AG (DE) 2007-05-16 EP disclosed
EP-1785420-A1 Thiazole analogues and uses thereof 4SC AG (DE) 2007-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149523-A1 Thiazole Analogues and Uses Thereof NR3C2, SLC26A4, CLIC4 AURKA 2397/4885EGFR 186/4885KDR 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.